Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

December 14, 2023 Rich Daly, Editor in Chief Views

Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!